

B4
SUB C5)

18. (amended)

A process for preparing infectious AAV vector preparations, comprising the steps of:

- a) preparing a viral vector which is based on adeno-associated viruses (AAVs)
- b) preparing a recombinant herpesvirus as claimed in claim 30
- c) introducing the AAV vector from (a) and the recombinant herpesvirus from (b) into a cell,
- d) replicating the AAV vector, and
- e) obtaining an infectious AAV vector preparation.

B5
SUB C6)

23. (amended)

A cell, which contains a recombinant herpesvirus as claimed in claim


30.

REMARKS

This amendment is made to again present the claims that were amended during the International phase. Examination should proceed based on these claims.

In the event any fees are required, please charge our Deposit Account No. 01-2300.

Respectfully submitted,
Arent Fox Kintner Plotkin & Kahn, PLLC


Robert B. Murray
Registration No. 22,980

1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339

(202) 857-6000

RBM/cb

MARKED UP CLAIMS

2. A recombinant herpesvirus as claimed in claim [1] 30, which does not exhibit any reversion to the wild type.
3. A recombinant herpesvirus as claimed in claim [1] 30, which additionally comprises a reporter gene.
4. A recombinant herpesvirus as claimed in claim [1] 30, which is selected from the group of Herpesviridae comprising herpes simplex virus (HSV), cytomegalovirus (CMV), pseudorabies virus (PRV) and Epstein-Barr virus (EBV) and other members of the herpesvirus family.
7. A recombinant herpesvirus as claimed in claim [1] 30, which is a mutant which is completely or partially replication-deficient.
8. A recombinant herpesvirus as claimed in claim [1] 30, wherein the insertion does not encompass the complete AAV ITR sequence.
9. A recombinant herpesvirus as claimed in claim [1] 30, wherein the AAV rep gene and the AAV cap gene are inserted in the U_L or the U_S region of the herpesvirus.
10. A process for preparing a recombinant herpesvirus as claimed in claim [1] 30,

wherein the AAV rep gene and the AAV cap gene are stably integrated into the genome of a herpesvirus.

15. A vector, which comprises a nucleic acid as claimed in claim [14] 31.
16. A viral composition which comprises a recombinant herpesvirus as claimed in claim [1] 30.
18. A process for preparing infectious AAV vector preparations, comprising the steps of:
 - a) preparing a viral vector which is based on adeno-associated viruses (AAVs)
 - b) preparing a recombinant herpesvirus as claimed in claim [1] 30
 - c) introducing the AAV vector from (a) and the recombinant herpesvirus from (b) into a cell,
 - d) replicating the AAV vector, and
 - e) obtaining an infectious AAV vector preparation.
23. A cell, which contains a recombinant herpesvirus as claimed in claim [1] 30.